Please login to the form below

Not currently logged in
Email:
Password:

Teva and Novartis settle patent lawsuit

Teva Pharmaceuticals will settle patent litigation with Novartis involving Teva's US generic version of antiviral medication Famvir

Teva Pharmaceuticals, US, has signed an agreement with Novartis to settle patent litigation involving Teva's US generic version of the Novartis-developed antiviral medication Famvir (famciclovir).

The settlement includes all claims for patent infringement and damages.

Under the terms of the agreement, Israel-based Teva will make an undisclosed one-time payment to Novartis plus ongoing royalties on US sales of its product, which is used to treat herpes and shingles.

Teva is among the top 15 global pharmaceutical companies and is a leading generic pharmaceutical company. Teva launched the generic version of Famvir in September 2007.

16th February 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics